Nafamostat mesylate

PI-040-10MG 10mg 65.00 GBP
PI-040-50MG 50mg 225.00 GBP

Product specification

Sequence: 4-[(Aminoiminomethyl)amino]benzoic acid 6-(aminoiminomethyl)-2-naphthalenyl ester dimethanesulfonate
MW: 539.59
Purity: >98% by tlc
Appearance: White solid
Formula: C19H17N5O2.2CH4O3S
CAS: 82956-11-4
Solubility Soluble to 100 mM in water and to 100 mM in DMSO
Long Term Storage: We recommend storage desiccated, frozen and in the dark

Nafamostat mesylate is a serine protease inhibitor.  It inhibits a large number of Lys/Arg specific serine proteinases, and is also a tryptase inhibitor.  In vivo nafamostat is a fast-acting proteolytic inhibitor and used during hemodialysis to prevent the proteolysis of fibrinogen into fibrin.  Nafamostat also has some antiviral and anti-cancer properties and has been identified as a potential treatment for COVID-19.

Product Literature References

Sendo et al (2003) A potent tryptase inhibitor nafamostat mesilate dramatically suppressed pulmonary dysfunction induced in rats by a radiographic contrast medium. Br. J. Pharmacol. 138 959 PMID: 12642398

Chen et al (2006) Serine protease inhibitors nafamostat mesilate and gabexate mesilate attenuate allergen-induced airway inflammation and eosinophilia in a murine model of asthma. J. Allergy Clin. Immunol. 118 105 PMID: 16815145

Wang et al (2020) Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 30(3) 269 doi:10.1038/s41422-020-0282-0